Embecta

Embecta Operating Expenses

The Total Operating Expenses of Embecta (EMBC) as of Nov 21, 2026 is 339.50 M USD. In the previous year, Total Operating Expenses was 434.90 M USD — a change of -21.94% (lower).

Operating Expenses

339.50 MUSD

YoY

-21.94%

Last updated:

Total Operating Expenses of Embecta is 2025 339.50 M USD. Total Operating Expenses of Embecta was 2024 434.90 M USD. It decreases by -21.94% lower compared to the previous year.

The Embecta Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
284.00 M USD
Jan 1, 2020
61.30 M USD
Jan 1, 2021
63.30 M USD
Jan 1, 2022
348.20 M USD
Jan 1, 2023
411.00 M USD
Jan 1, 2024
434.90 M USD
Jan 1, 2025
339.50 M USD
The Embecta Operating Expenses history
YEAROperating ExpensesYoY
339.50 MUSD-21.94%
434.90 MUSD+5.82%
411.00 MUSD+18.04%
348.20 MUSD+450.08%
63.30 MUSD+3.26%
61.30 MUSD-78.42%
284.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Total Operating Expenses of Embecta is 339.50 M USD in 2025.

Total Operating Expenses of Embecta changed from 434.90 M USD to 339.50 M USD, representing a -21.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Embecta since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Embecta

All Key Metrics — Embecta